Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,624 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: dATS Clear all
Completed Phase 1 Interventional

Salsalate in Patients Mild to Moderate Alzheimer's Disease

NCT03277573
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Salsalate, Placebo
Drug
Lead sponsor
Adam Boxer
Other
Eligibility
50 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
San Diego, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 25, 2026, 8:59 PM EDT
Completed Not applicable Interventional Results available

Using Technology to Support Care Partners for Persons With Alzheimer's Disease: Tele-STELLA

NCT04627662
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Caregiver Burnout, Family Members
Interventions
Tele-STELLA
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 25, 2026, 8:59 PM EDT
Completed Phase 2 Interventional

Tricaprilin in Mild to Moderate Alzheimer's Disease

NCT00142805
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Tricaprilin, Placebo
Drug · Other
Lead sponsor
Cerecin
Industry
Eligibility
50 Years to 90 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
25
States / cities
Phoenix, Arizona • Cerritos, California • Los Alamitos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 25, 2026, 8:59 PM EDT
Completed No phase listed Observational

A Study to Determine the Signs and Symptoms That Impact Daily Life of Participants With Irregular Sleep-Wake Rhythm Disorder

NCT04300569
View directory record Official record
Conditions
Irregular Sleep Wake Rhythm Disorder
Interventions
Non-interventional
Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
6
States / cities
Costa Mesa, California • San Diego, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 25, 2026, 8:59 PM EDT
Completed Phase 4 Interventional Results available

Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly

NCT01951118
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders
Interventions
Donepezil
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 25, 2026, 8:59 PM EDT
Completed Phase 1 Interventional

Study to Evaluate DNL747 in Subjects With Alzheimer's Disease

NCT03757325
View directory record Official record
Conditions
Alzheimer Disease
Interventions
DNL747, Placebo
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 25, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Results available

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

NCT01193608
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AAB-003 (PF-05236812), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 89 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
23
States / cities
Escondido, California • Hallandale, Florida • Ocala, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 25, 2026, 8:59 PM EDT
Completed Phase 3 Interventional

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT03393520
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
Placebo, AVP-786
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
93
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 25, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Results available

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

NCT01369225
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AAB-003 (PF-05236812)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Hallandale, Florida • Ocala, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 25, 2026, 8:59 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

NCT06079190
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
GSK4527226, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 85 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
21
States / cities
San Diego, California • Lake Mary, Florida • Lake Worth, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 25, 2026, 8:59 PM EDT
Terminated Phase 2 Interventional

Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease

NCT00021723
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AN-1792 also known as AIP-001
Biological
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
11
States / cities
Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Oct 25, 2026, 8:59 PM EDT
Terminated Phase 1 Interventional

Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment

NCT02573740
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
ABT-957, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Cypress, California • Orlando, Florida • The Villages, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 25, 2026, 8:59 PM EDT
Completed Not applicable Interventional Results available

Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints

NCT00597376
View directory record Official record
Conditions
Subjective Memory Loss in Older Persons
Interventions
Cerefolin NAC (a medical food), Cerefolin NAC placebo
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
60 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Oct 25, 2026, 8:59 PM EDT
Not yet recruiting Not applicable Interventional

SmartEnLite for Nursing Home Residents With Dementia

NCT07883291
View directory record Official record
Conditions
Alzheimer's Disease and Related Dementias, Alzheimer Disease and Related Dementias
Interventions
Smart Environmental Light (SmartEnLite)
Device
Lead sponsor
Penn State University
Other
Eligibility
55 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 8:59 PM EDT
Completed Not applicable Interventional

A Dyadic Sleep Intervention for Alzheimer's Disease Patients and Their Caregivers

NCT03455569
View directory record Official record
Conditions
Sleep, Alzheimer Disease
Interventions
Behavioral sleep education, Education only
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Los Angeles, California • North Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 25, 2026, 8:59 PM EDT
Completed Phase 2 Interventional

Behavioral Sleep Intervention in Adult Family Homes

NCT00393627
View directory record Official record
Conditions
Dementia
Interventions
Sleep Education Program
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 25, 2026, 8:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

BCT Intervention For Walking Habit Among Caregivers of People With AD/ADRD

NCT06803797
View directory record Official record
Conditions
Inactivity, Physical
Interventions
Behavior Change Technique Package
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 25, 2026, 8:59 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Beyond Listening: A Music-based Intervention

NCT04840173
View directory record Official record
Conditions
Alzheimer's Disease (Incl Subtypes), Depressive Symptoms
Interventions
Music
Behavioral
Lead sponsor
MJHS Institute for Innovation in Palliative Care
Other
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 25, 2026, 8:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Family Quality of Life Through Training to Reduce Care-Resistant Behaviors by People With AD and TBI

NCT03734289
View directory record Official record
Conditions
Dementia, Traumatic Brain Injury
Interventions
Caregiver Coaching
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 25, 2026, 8:59 PM EDT
Completed Phase 1 Interventional

Low Dose IL2 Immunotherapy in AD

NCT05821153
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Aldesleukin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
60 Years to 86 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 25, 2026, 8:59 PM EDT
Completed Phase 1 Interventional

Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease

NCT01397539
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
BIIB037, Placebo
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
55 Years to 85 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Delray Beach, Florida • Orlando, Florida • Beachwood, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 25, 2026, 8:59 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Alzheimer's Disease

NCT02912169
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Liposuction under local anesthesia, Infusion of AD-SVF via IV and Intranasal
Procedure · Biological
Lead sponsor
Ageless Regenerative Institute
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 25, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available

A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease

NCT02167256
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AZD0530 100mg daily, AZD0530 125mg daily, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
55 Years to 85 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
21
States / cities
Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 25, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Results available

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

NCT00478205
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aricept (donepezil SR 23 mg), Aricept (donepezil IR 10 mg)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
1,467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 25, 2026, 8:59 PM EDT